Another subsidiary of The Micro-Invascope Medical Spin-Off has recently been listed three times

Pharmaceutical Network December 16 - Micro-Invasive Medical continues to split recently, Micro-Invasive Medical announced that it is considering a possible spin-off of the company's non-whowicial subsidiary Micro-Invasive (Shanghai) Medical Robotics Co., Ltd. ("Micro-Invasive Medical Robotics") and its shares listed independently on an accredited stock exchange.
According to minimally invascopic medical semi-annual report 2020, minimally invascopic medical services include cardiovascular intervention products business, orthopaedic medical device business, heart rhythm management medical device business, aortic and extrinsic vascular intervention products business, neuro-intervention products business, heart valve business and surgical robots.
and its affiliates are engaged in the development and commercialization of surgically assisted robots.
, minimally invascopic medical robots were established in 2014 and cover the five main tracks of laparoscopy, orthopaedics, vascular intervention, natural cavity, and persepassion, according to the official website.
the first half of 2020, the minimally invasible medical surgical robotics business reported a net loss of $2.309 million.
's current three flagship products of minimally invasable medical robots, eye ™DFVision™ 3D electronic laparoscopy, Tumei™Toumai™ laparoscopic surgery robot, Hongxuan ™Skywalker™ joint replacement surgery robot, have entered the National Drug Administration innovative medical device green channel.
In April, minimally invascopic medical robots reached a strategic cooperation agreement with Robocath, a French vascular interventional surgery robot, and established a joint venture in China to produce and assemble robotics systems in China and develop next-generation robotics systems and related artificial intelligence technologies.
August 31 this year, the micro-invassed medical robots of the Micro-Invascopic Medical Association officially signed a total of RMB 3 billion in external financing agreements.
The market is about to explode it is understood that surgical robots are a kind of medical robots that can be used for surgical imaging guidance and minimally invasive surgery, on the one hand, surgical robots can overcome traditional surgical accuracy, long time, easy fatigue, lack of 3D medical image navigation and other technical defects;
according to China Industry Information Network, the most widely used surgical robot in the world is the Da Vinci surgical machine man produced by IntuitiveSurgical.
since the first generation of Leonardo da Vinci surgical robots was approved by the FDA in July 2000, Intuitive Surgical has developed and designed five generations of Da Vinci surgical robots.
Grand View Research shows that the surgical robot market will reach $5.6 billion by 2025.
report says the market for surgical robots will explode, and that innovative robots will cover the entire process from diagnosis to surgery, reshaping medicine.
China's medical robot industry started late, from 1997 China completed the first robot surgery to 2010 the first fully independent intellectual property rights of the medical robot "orthopaedic navigation robot" to obtain a national medical device registration license and put into clinical use, China's medical robot industry to accelerate the process of independent innovation.
, China's surgical robot industry has maintained a high growth rate in recent years, with the market size of the surgical robot industry reaching 619 million yuan in 2019, up 40.6% year-on-year, according to the data.
China's domestic surgical robots have developed rapidly, with the domestic surgical robot market reaching 323 million yuan in 2019, and the proportion of domestic surgical robots increasing from 20.58 percent in 2016 to 52.16 percent in 2019.
But there are still many problems to be solved in the field of surgical robots, China Industrial Information Network analysis, surgical robots are more expensive, and the cost of surgery basically need to take care of themselves, has not been included in health insurance, the prevalence and uity rate in China is still low.
addition, the development of surgical robots in China still faces adverse factors such as the price threshold for surgical robots to enter medical institutions, the high cost of robot surgery, and the monopoly of intellectual property rights restricting the research and development cost of domestic surgical robots.
siyu medical equipment observation has also analyzed, in reality, the promotion of surgical robots is not so easy.
On the one hand, surgical robots are not only expensive equipment, supplies and related services are much higher than traditional surgery, resulting in high surgical costs;
the domestic armed enterprises to split the domestic armed enterprises to split the listing action frequently, coupled with this time, the recent minimally invascope medical has three split listing action.
November 9th, MicroPortCardioFlow Medical Corporation, a subsidiary of the company, announced that it proposed to spin off its stake in MicroPortCardioFlowMedtech Corporation, which is listed separately on the main board of the Stock Exchange.
micro-invasive heart is mainly engaged in research and development, manufacturing and sales of treatment valve heart disease equipment business.
2019 Annual Report shows that by the end of 2019, the micro-invasive medical heart valve business achieved revenue of US$3.1 million, or about RMB20 million, and the 2020 half-year report showed that the heart valve business achieved revenue of US$5.2 million, or about RMB34 million, accounting for 1.7% of total revenue, surpassing the surgical medical device business as the sixth largest business section of minimally invasive medical care.
, in 2019 Microinvascopic Healthcare also split its aortic and exovascular intervention business, with subsidiary Heartline Medical listed on the tablet.
according to the prospector, cardiovascular medicine in China's aortic vascular intervention medical device field ranked first.
2016-18, Heartline Healthcare's revenue was approximately $1.25 billion, $1.65 billion and $2.31 billion, respectively, with a compound growth rate of 136%, and its aortic stent sales revenue as a percentage of total revenue has been around 80%.
addition to minimally invascope healthcare, Vigo and Lepu are both in the process of splitting up recently.
December 1, Seber Blue Devices inquiry on the official website of the Shanghai Stock Exchange found that Lepu Medical subsidiary Beijing Lepu Diagnostic Technology Co., Ltd. officially issued a prospecto.
Lep Medical has issued a statement that the split is partly because Lep Medical will further focus on the main industry to improve market competitiveness, on the other hand, Lepu Diagnostics will also be independent of other business sectors - from Lepu Medical revenue can be seen in the impact of the new crown outbreak, Lepu Diagnostics business increased, but the main business of medicine and cardiovascular stents is affected.
September 15th, Shandong Vigo announced that it was considering a possible spin-off of its one-off medical device business in radiology, vascular, cardiology and oncology intervention surgery.
June 11, Shandong Weigao announced that it proposed to spin off Shandong Weigao Orthopaedic Materials Co., Ltd. and independently listed on the Board.
board announced at the time that Vico Orthopaedics had submitted an application to the Shanghai Stock Exchange for listing on the board.
we have a wide range of products, including clinical care, trauma management, blood management, pharmaceutical packaging, medical testing, anaesthetic and surgical-related products, orthopaedics and intervention products in eight major business areas.
according to the annual report, in 2019, Shandong Weigao Orthopaedics business achieved a turnover of about 1.556 billion yuan, an increase of 31.8% over 2018, and in the first half of 2020, Shandong Weigao Orthopaedics business achieved revenue of about 830 million yuan, an increase of 21.8% over the same period last year.
。